IP Library Granted Patent US 7,763,427
Granted Patent B2
US 7,763,427 · App. 12/151,741 · Granted Jul 27, 2010

Detection of recombinase polymerase amplification products

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,763,427
App. No.
12/151,741
Granted
Jul 27, 2010
Kind
B2
Abstract

This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length.

Claims (32)

1. A process of detecting the presence or absence of a recombinase polymerase amplification amplified target nucleic acid, comprising the steps of:

(a) contacting a recombinase agent with a first and second nucleic acid primer to form a first and second nucleoprotein primer, wherein each of said nucleic acid primers comprise a single stranded region at its 3′ end, wherein said first nucleic acid primer is labeled with a first member of a first binding pair, and wherein said second nucleic acid primer is labeled with a first member of a second binding pair;

(b) contacting the first and the second nucleoprotein primers to a sample suspected to contain an amplified target nucleic acid amplified by a recombinase polymerase amplification (RPA) process to form complexes with a first and a second nucleoprotein primer/target nucleic acid structure at a first portion and a second portion of said amplified target nucleic acid, respectively, and wherein said recombinase polymerase amplification process is performed in the presence of a crowding agent such that the crowding agent stimulates amplification;

(c) contacting said complexes with a first mobile solid support coated with a second member of said first binding pair and a second mobile solid support coated with a second member of said second binding pair;

(d) determining if said first mobile solid support is co-localized with said second mobile solid support to determine the presence of said recombinase polymerase amplification amplified target nucleic acid.

2. The process of claim 1 wherein the first nucleic acid primer has the same nucleic acid sequence as a primer used to produce the suspected recombinase polymerase amplification amplified target nucleic acid.

3. The process of claim 1 wherein the second nucleic acid primer has the same nucleic acid sequence as a primer used to produce the suspected recombinase polymerase amplification amplified target nucleic acid.

4. The process of claim 1 wherein the first and/or second primers at said first and/or said second nucleoprotein primer/target nucleic acid structure(s), respectively, form a triple helix mediated by said recombinase agent, and said triple helix formation occurring after amplification of the target nucleic acid by said recombinase polymerase amplification process.

5. The process of claim 1 wherein the amplification of said amplified target nucleic acid by said RPA process is selected from the group consisting of at least 10 fold, at least 100 fold, at least 1000 fold, at least 10,000 fold, at least 100,000 fold and at least 1000000 fold.

6. The process of claim 1 wherein said recombinase agent is a uvsX recombinase.

7. The process of claim 1 wherein said RPA process is performed using a DNA polymerase I.

8. The process of claim 1 wherein said RPA process is performed using a gp32 protein single stranded DNA binding protein.

9. The process of claim 1 wherein said RPA process is performed using a uvsY recombinase loading protein.

10. The process of claim 1 wherein said RPA process comprises the steps of:

(a) combining the following reagents with a sample suspected to contain said target nucleic acid

(1) said recombinase agent;

(2) at least one single stranded DNA binding protein;

(3) at least one DNA polymerase;

(4) dNTPs or a mixture of dNTPs and ddNTPs;

(5) a crowding agent such that the crowding agent stimulates amplification;

(6) a buffer;

(7) a reducing agent;

(8) ATP or hydrolysable ATP analog; and

(9) at least one recombinase loading protein;

(b) incubating said sample until a desired degree of amplification is achieved.

11. The process of claim 10 wherein the reagents combined with the sample suspected to contain said target nucleic acid also include a third primer and optionally a fourth primer.

12. The process of claim 10 wherein said recombinase agent is a uvsX recombinase.

13. The process of claim 10 wherein said at least one DNA polymerase is a DNA polymerase I.

14. The process of claim 10 wherein said at least one DNA polymerase is a DNA polymerase with strand-displacing properties and which lacks 5′ to 3′ exonuclease activity.

15. The process of claim 10 wherein said at least one single stranded DNA binding protein is a gp32 protein single stranded DNA binding protein.

16. The process of claim 10 wherein said at least one recombinase loading protein is a uvsY recombinase loading protein.

17. The process of claim 10 wherein said recombinase agent is a uvsX recombinase, said at least one DNA polymerase is a DNA polymerase I, said at least one single stranded DNA binding protein is a gp32 protein single stranded DNA binding protein, and said at least one recombinase loading protein is a uvsY recombinase loading protein.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ALERE SAN DIEGO INC.
To: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
Reel/Frame 054604/0936 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
CHANGE OF NAME Recorded Sep 30, 2010
From: BIOSITE INCORPORATED
To: ALERE SAN DIEGO, INC.
Reel/Frame 025066/0698 →
CHANGE OF NAME Recorded Sep 30, 2010
From: ASM SCIENTIFIC, INC.
To: TWISTDX, INC.
Reel/Frame 025066/0515 →
CERTIFICATE OF MERGER Recorded Sep 30, 2010
From: TWISTDX, INC.
To: BIOSITE INCORPORATED
Reel/Frame 025066/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: PIEPENBURG, OLAF; WILLIAMS, COLIN H.; ARMES, NIALL A.; STEMPLE, DEREK L.
To: ASM SCIENTIFIC, INC.
Reel/Frame 025063/0667 →
SECURITY AGREEMENT Recorded Sep 15, 2010
From: ALERE SAN DIEGO, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 024982/0841 →
SECURITY AGREEMENT Recorded Sep 15, 2010
From: ALERE SAN DIEGO, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 024990/0030 →